Ironwood Pharmaceuticals initiated an internal organizational restructuring that includes cutting up to 100 full-time employees from payroll following a review of unblinded data from the company’s Phase III trials for IW-3718-302, which show that the drug failed to reduce the severity of heartburn in patients with refractory gastroesophageal reflux disease (GERD).
23andMe announced that the company was laying off about 100 employees as sales were down, reflecting a shrinking market for DNA test kits to consumers.
Amgen filed a Worker Adjustment and Retraining in California with plans to cut 172 jobs at the company’s headquarters and U.S. field operations effective December 31, 2019.
Amgen filed a Worker Adjustment and Retraining (WARN) filing with the Commonwealth of Massachusetts, indicating the company planned to lay off 149 employees effective December 31, 2019.
Netherlands-based Kiadis Pharma is discontinuing Phase III development of lead T-cell asset ATIR101 and laying off half of the company’s staff, seven months after acquiring CytoSen.
Halozyme Therapeutics is restructuring after halting development of a metastatic pancreatic cancer drug that failed to demonstrate an improvement in overall survival in a Phase III trial.
Acorda Therapeutics will terminate approximately 25 percent of headcount as the company initiates a corporate restructuring.
Merck will slash about 500 jobs in early 2020 at two Montgomery County, Pa., facilities as well as in some other states, Pennsylvania’s Morning Call reported.
Less than a month after the company’s Phase III brain cancer treatment failed, San Diego-based Tocagen is undergoing a restructuring and will reduce the employee workforce by 65 percent.
Two weeks after the U.S. FDA rejected Acer Therapeutics’ New Drug Application for Edsivo (celiprolol), the company initiated a restructuring plan that includes the elimination of 29 employees.